Priming systemic anti-tumor immunity via in situ immunomodulation of the tumor microenvironment
Systemic cancer immunotherapies including checkpoint blockade antibodies targeting the PD-1/PD-L1 axis and CTLA-4 have improved survival outcomes in a subset of cancer patients by driving tumor-directed immune responses. However, many patients do not benefit from such immunotherapies due to immune r...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Published: |
Massachusetts Institute of Technology
2022
|
| Online Access: | https://hdl.handle.net/1721.1/139220 |